U.S. Food And Drug Administration (FDA)

How to talk with patients about how long IUDs and implants work, and what to say when the evidence goes beyond the FDA label.

Partner treatment for recurrent BV, ACOG contraceptive access update, de-implementing early pregnancy RhIG, tampon use with contraceptive vaginal rings, WHO MEC and SPR updates

DMPA on TikTok, OTC pill sales, Misoprostol & IUD placements, Telehealth abortion & TGD populations, Abortion restrictions & infant mortality

Contraceptive knowledge gaps, Adolescent awareness of OTC contraception, DMPA and meningioma risk, Implicit bias in contraception counseling, PrEP & STI Risk

HPV self-collection, asynchronous telehealth abortion studies, young people and permanent contraception access, clinician confidence gaps in abortion navigation, shifting contraceptive preferences postpartum

Answers for pharmacists (and other providers) about the current status of mifepristone.

What providers need to know about the December 2022 updates to levonorgestrel emergency contraception (LNG-EC) labeling.

Continued support for misoprostol-only regimens for medication abortion and self-managed abortion between nine and 16 weeks gestation, the use of home pregnancy tests for follow-up care after a telehealth medication abortion, where adolescents and young adults go online to get abortion information, and disparities in recommended retesting for women with trichomonas vaginalis infections.